BamSEC and AlphaSense Join Forces
Learn More

CytomX Therapeutics Inc. – Material Contracts

NASDAQ: CTMX    
Share price (5/22/26): $3.76    
Market cap (5/22/26): $819 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.17(B)
from 10-K 3 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) May Be Competitively Harmful if Publicly Disclosed. November 20, 2025 Mr. Eliot Green Vp, Business Development Modernatx, Inc. 325 Binney Street Cambridge, Massachusetts 02142 USA via Email To: [***]
12/34/56
EX-10.8
from 10-K 4 pages September 16, 2025 Total Rewards: Compensation
12/34/56
EX-10.2
from 10-Q 99 pages Office/Laboratory Lease Between Emery Station West, LLC (Landlord) and CytomX Therapeutics, Inc. (Tenant) Emerystation West 5959 Horton Street Emeryville, California
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 2 to the Collaboration and License Agreement
12/34/56
EX-10.2
from 10-Q 8 pages CytomX Therapeutics, Inc. Amended and Restated Employee Stock Purchase Plan 1
12/34/56
EX-10.2
from 8-K 9 pages CytomX Therapeutics, Inc. Amended and Restated Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 17 pages CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan Adopted by Board: September 17, 2015 Approved by Stockholders: October 2, 2015 Amended and Restated: March 19, 2025
12/34/56
EX-10.1
from 10-Q 9 pages Separation Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment No. 1 to the Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment No. 4 to the Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 15 pages Transition Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Sent via Docusign March 13, 2021 Total Rewards: Compensation
12/34/56
EX-10.2
from 10-Q 7 pages Amended and Restated Severance and Change of Control Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment No. 3 to the Collaboration and License Agreement Part 1 - Amendments to Certain Terms
12/34/56
EX-10.1
from 8-K 55 pages Unit Purchase Agreement
12/34/56
EX-10
from 10-Q 16 pages 2. Premises: A
12/34/56
EX-10
from 10-K 65 pages Collaboration and License Agreement by and Between CytomX Therapeutics, Inc. and Modernatx, Inc. Dated as of December 30, 2022
12/34/56
EX-10
from 10-K 67 pages Collaboration and License Agreement by and Between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Dated as of November 16, 2022
12/34/56
EX-10.6
from 10-Q 8 pages Amendment No 3 to Collaboration and License Agreement
12/34/56
EX-10.5
from 10-Q 8 pages September 30, 2022 Alison Hannah, M.D. [***] Re: Employment Separation Dear Alison
12/34/56